<p>During the 67th American&nbsp;Society of Hematology&nbsp;(ASH)&nbsp;Annual Meeting and Exposition,&nbsp;December 6–9, 2025, Orlando, US,&nbsp;the MPN Hub was pleased to speak with&nbsp;<a href="https://mpn-hub.com/contributors/jean-jacques-kiladjian" rel="noopener noreferrer" target="_blank">Jean-Jacques Kiladjian</a>,&nbsp;Université Paris Cité, Paris, FR. We asked,&nbsp;What&nbsp;are the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study?&nbsp;</p><br><p>In this interview,&nbsp;Kiladjian&nbsp;first provided&nbsp;an overview of the phase III&nbsp;<a href="https://mpn-hub.com/trials/rop-et" rel="noopener noreferrer" target="_blank">ROP-ET</a>&nbsp;(<a href="https://clinicaltrials.gov/study/NCT06514807" rel="noopener noreferrer" target="_blank">NCT06514807</a>)&nbsp;study design and key patient eligibility criteria.&nbsp;He&nbsp;then discussed&nbsp;the primary endpoint results,&nbsp;highlighting that the ROP-ET study met the primary endpoint&nbsp;–&nbsp;a&nbsp;composite durable hematologic and clinical response after 12 months.&nbsp;Finally,&nbsp;Kiladjian&nbsp;explored&nbsp;the safety profile of&nbsp;<a href="https://mpn-hub.com/therapeutics/immune-modulators/ropeginterferon-alfa-2b" rel="noopener noreferrer" target="_blank">ropeginterferon&nbsp;alfa-2b</a>&nbsp;observed&nbsp;in the study.</p><br><p><em>This educational resource is independently supported by AOP Health. All content was developed by SES in collaboration with an expert steering committee. Funders were&nbsp;allowed&nbsp;no influence on the content of this resource.</em>&nbsp;</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>